Quetzal Chavez-Castañeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Quetzal Chavez-Castañeda has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Brenda Ofelia Jay-Jímenez
Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
4 shared publications - Héctor Iván Saldívar-Cerón
Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
4 shared publications - Sonia Leon-Cabrera
Unidad de Biomedicina (UBIMED), Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
4 shared publications - Ari Evelyn Castañeda-Ramírez
Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
3 shared publications - Adolfo René Méndez-Cruz
Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
2 shared publications - Alejandra Hernández-Solís
Unidad de Remisión de Diabetes Mellitus (URDM), Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9654
From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, receptor-specific causal attribution, and the unresolved limitations of translating molecular pharmacology into durable clinical benefit. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.
- 28 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9654
Open AccessFrom Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, receptor-specific causal attribution, and the unresolved limitations of translating molecular pharmacology into durable clinical benefit. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.
- Open Access
- 5 October 2026
- Published by MDPI AG in Preprints.org
From Oxyntomodulin to Retatrutide: Engineering Metabolic Polyagonism
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, and the unresolved attribution of clinical effects to individual receptor components. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.
- 5 October 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Oxyntomodulin to Retatrutide: Engineering Metabolic Polyagonism
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, and the unresolved attribution of clinical effects to individual receptor components. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.
- Open Access
- 7 August 2025
- Published by MDPI AG in European Journal of Investigation in Health, Psychology and Education
- Vol. 15 (8) , 152
DIALOGUE: A Generative AI-Based Pre–Post Simulation Study to Enhance Diagnostic Communication in Medical Students Through Virtual Type 2 Diabetes Scenarios
DIALOGUE (DIagnostic AI Learning through Objective Guided User Experience) is a generative artificial intelligence (GenAI)-based training program designed to enhance diagnostic communication skills in medical students. In this single-arm pre–post study, we evaluated whether DIALOGUE could improve students’ ability to disclose a type 2 diabetes mellitus (T2DM) diagnosis with clarity, structure, and empathy. Thirty clinical-phase students completed two pre-test virtual encounters with an AI-simulated patient (ChatGPT, GPT-4o), scored by blinded raters using an eight-domain rubric. Participants then engaged in ten asynchronous GenAI scenarios with automated natural-language feedback. Seven days later, they completed two post-test consultations with human standardized patients, again evaluated with the same rubric. Mean total performance increased by 36.7 points (95% CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0% to 70%. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes specific explanation. Multiple regression showed that lower baseline empathy (β = −0.41, p = 0.005) and higher digital self-efficacy (β = 0.35, p = 0.016) independently predicted greater improvement; gender had only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain group characterized by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated training can meaningfully enhance diagnostic communication and may serve as a scalable, individualized adjunct to conventional medical education.
- 7 August 2025
- Published by MDPI AG in European Journal of Investigation in Health, Psychology and Education
- Vol. 15 (8) , 152
Open AccessDIALOGUE: A Generative AI-Based Pre–Post Simulation Study to Enhance Diagnostic Communication in Medical Students Through Virtual Type 2 Diabetes Scenarios
DIALOGUE (DIagnostic AI Learning through Objective Guided User Experience) is a generative artificial intelligence (GenAI)-based training program designed to enhance diagnostic communication skills in medical students. In this single-arm pre–post study, we evaluated whether DIALOGUE could improve students’ ability to disclose a type 2 diabetes mellitus (T2DM) diagnosis with clarity, structure, and empathy. Thirty clinical-phase students completed two pre-test virtual encounters with an AI-simulated patient (ChatGPT, GPT-4o), scored by blinded raters using an eight-domain rubric. Participants then engaged in ten asynchronous GenAI scenarios with automated natural-language feedback. Seven days later, they completed two post-test consultations with human standardized patients, again evaluated with the same rubric. Mean total performance increased by 36.7 points (95% CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0% to 70%. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes specific explanation. Multiple regression showed that lower baseline empathy (β = −0.41, p = 0.005) and higher digital self-efficacy (β = 0.35, p = 0.016) independently predicted greater improvement; gender had only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain group characterized by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated training can meaningfully enhance diagnostic communication and may serve as a scalable, individualized adjunct to conventional medical education.
- Open Access
- 10 July 2025
- Published by MDPI AG in Preprints.org
DIALOGUE: A Generative AI–Based Pre–Post Simulation Study to Improve Diagnostic Communication in Medical Students Using Type 2 Diabetes Scenarios
Effective diagnostic communication—delivering a diagnosis with clarity, structure, and empathy—remains a challenging competency for many undergraduate medical students. This single-arm pre–post study evaluated a generative artificial-intelligence (GenAI) training module designed to improve diagnostic-communication performance. Thirty clinical-phase students completed two pre-test encounters in which they disclosed a type 2 diabetes mellitus (T2DM) diagnosis to a virtual patient powered by ChatGPT (GPT-4o) and were scored with an eight-domain rubric by blinded raters. They then undertook ten asynchronous GenAI scenarios with automated natural-language feedback, followed seven days later by two post-test consultations with human standardized patients assessed in real time with the same rubric. Mean total performance increased by 36.7 points (95 % CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0 % to 70 %. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes-specific explanation. Multiple regression showed that lower baseline empathy (β = –0.41, p= 0.005) and higher digital self-efficacy (β = 0.35, p= 0.016) inde-pendently predicted greater improvement; gender displayed only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain cluster character-ised by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated practice can produce meaningful, measurable enhancements in diagnostic-communication skills and may serve as a scalable, individualised adjunct to conventional clinical education.
- 10 July 2025
- Published by MDPI AG in Preprints.org
Open AccessDIALOGUE: A Generative AI–Based Pre–Post Simulation Study to Improve Diagnostic Communication in Medical Students Using Type 2 Diabetes Scenarios
Effective diagnostic communication—delivering a diagnosis with clarity, structure, and empathy—remains a challenging competency for many undergraduate medical students. This single-arm pre–post study evaluated a generative artificial-intelligence (GenAI) training module designed to improve diagnostic-communication performance. Thirty clinical-phase students completed two pre-test encounters in which they disclosed a type 2 diabetes mellitus (T2DM) diagnosis to a virtual patient powered by ChatGPT (GPT-4o) and were scored with an eight-domain rubric by blinded raters. They then undertook ten asynchronous GenAI scenarios with automated natural-language feedback, followed seven days later by two post-test consultations with human standardized patients assessed in real time with the same rubric. Mean total performance increased by 36.7 points (95 % CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0 % to 70 %. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes-specific explanation. Multiple regression showed that lower baseline empathy (β = –0.41, p= 0.005) and higher digital self-efficacy (β = 0.35, p= 0.016) inde-pendently predicted greater improvement; gender displayed only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain cluster character-ised by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated practice can produce meaningful, measurable enhancements in diagnostic-communication skills and may serve as a scalable, individualised adjunct to conventional clinical education.